Insider Buying Boosts Confidence in Korro Bio’s RNA‑Therapeutics
Insider buying surges at Korro Bio as NEA 17 backs its RNA‑therapeutic platform, signaling confidence in future clinical milestones and potential upside.
4 minutes to read
Korro Bio Inc
Korro Bio Insider Buy‑The‑Share: COO Chappell Todd & Team Bet on RNA‑Therapy Upside
Insight: Korro Bio’s COO and top execs buy stock options—showing confidence in its RNA‑therapy pipeline and potential upside despite a volatile share price.
4 minutes to read